BIOMAT Database Logo BIOMAT Database Logo

[If Artificial Tears Aren't Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti-Inflammatory Therapy of Dry Eye Disease]. 2020

Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
Universitäts-Augenklinik, Charité - Campus Virchow-Klinik, Berlin.

Dry eye disease (DED) is a heterogenous disease of the ocular surface. Multiple pathogenetic factors are responsible for the disease process, but DED is generally linked to an increase in the osmolarity of the tear film and to inflammation of the ocular surface. The significance of inflammatory processes in DED is highlighted in the most recent definition of dry eye in the Dry Eye Workshop (DEWS). It is therefore critically important for the management of dry eye disease to understand the pathomechanisms and therapeutic options for the treatment of inflammatory processes. This review summarizes our current knowledge on Inflammation associated with DED and provides practical recommendations for the diagnosis and monitoring of the disease, as well as the use of currently available therapeutic options to counteract inflammation in DED.

UI MeSH Term Description Entries
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D013666 Tears The fluid secreted by the lacrimal glands. This fluid moistens the CONJUNCTIVA and CORNEA. Meibomian Lipids,Meibum,Lipid, Meibomian,Meibomian Lipid,Tear
D015352 Dry Eye Syndromes Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur. Dry Eye,Dry Eye Disease,Evaporative Dry Eye,Evaporative Dry Eye Disease,Evaporative Dry Eye Syndrome,Dry Eye Diseases,Dry Eye Syndrome,Dry Eye, Evaporative,Dry Eyes,Evaporative Dry Eyes
D065346 Lubricant Eye Drops Ophthalmic solutions that include LUBRICANTS and WETTING AGENTS such as POLYETHYLENE GLYCOL; HYPROMELLOSE; GLYCEROL; PROPYLENE GLYCOL. They are used to treat conditions caused by deficient tear production such as DRY EYE SYNDROME. Artificial Tear,Artificial Tears,Lubricant Eye Drop,Lubricating Eye Drop,Tears, Artificial,Lubricating Eye Drops,Drop, Lubricant Eye,Drop, Lubricating Eye,Drops, Lubricant Eye,Drops, Lubricating Eye,Eye Drop, Lubricant,Eye Drop, Lubricating,Eye Drops, Lubricant,Eye Drops, Lubricating,Tear, Artificial

Related Publications

Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
Personalized Management of Dry Eye Disease: Beyond Artificial Tears.
January 2022, Clinical ophthalmology (Auckland, N.Z.),
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
Anti-inflammatory therapy of dry eye.
January 2003, The ocular surface,
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
[Anti-inflammatory treatment in dry eye disease].
May 2012, Klinische Monatsblatter fur Augenheilkunde,
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.
January 2006, Eye & contact lens,
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
[Dry eye: an inflammatory disease?].
October 1999, Journal francais d'ophtalmologie,
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
When eyes get dry and what you can try. If artificial tears didn't work, anti-inflammatory cyclosporine drops may.
October 2010, Harvard health letter,
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease.
February 2022, International journal of molecular sciences,
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
Rationale for anti-inflammatory therapy in dry eye syndrome.
January 2008, Arquivos brasileiros de oftalmologia,
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
Advancements in anti-inflammatory therapy for dry eye syndrome.
October 2009, Optometry (St. Louis, Mo.),
Uwe Pleyer, and Gerd Geerling, and Stefan Schrader, and Christina Jacobi, and Friedemann Kimmich, and Elisabeth Messmer
Effectiveness of artificial tears in the management of evaporative dry eye.
January 2012, Cornea,
Copied contents to your clipboard!